Skip to content

Feature Detection Study for Validation of Hamamatsu NanoZoomer S360MD Digital Slide Scanner System

Clinical Validation for Feature Detection Precision by WSI Using Hamamatsu NanoZoomer S360MD Digital Slide Scanner System

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03992768
Enrollment
540
Registered
2019-06-20
Start date
2019-06-12
Completion date
2021-09-30
Last updated
2022-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pathology

Brief summary

The objective of this study is to evaluate the repeatability and reproducibility of detection of histological features using whole slide imaging

Detailed description

The study will be conducted under the following 3 sub-studies: 1. Scans within Scanner (Intra-scanner precision substudy), 2. Scanners within a site (Inter-scanner precision substudy), 3. Scanners between sites (Inter-site precision substudy)

Interventions

DEVICEHamamatsu NanoZoomer S360MD Digital Slide Scanner System

Detection of pathology features using whole slide imaging

Sponsors

Hamamatsu Photonics K.K.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

Glass slides are screened for the known features and will be considered eligible for the study only if all of the following criteria apply: * Slides are selected from cases in a consecutive manner starting with cases at least 1 year old since accessioning * Slide is a glass cover-slipped surgical pathology slide of human tissue * Slide is stained with hematoxylin and eosin (H&E) or other stains * Slide has the designated primary feature in the FOV, which is readily observable in its natural environment although the slide may also have one or more secondary features from the same magnification group in the FOV. * Slide is available in the archives for use, or purchased commercially, is not damaged, has tissue on the slide which is still in good condition, has a stain that is not faded and otherwise passes all quality checks

Exclusion criteria

Slides are to be excluded from the study if any of the following criteria apply: * Slide is unable to be scanned, contains damaged tissue or has indelible markings * Slide comes from an active (less than 1 year old) case * Slide is from a patient who already has a slide enrolled in the study, only 1 slide per patient to be enrolled

Design outcomes

Primary

MeasureTime frameDescription
Overall Percentage Agreement of Repeatability and Reproducibility Within Scanner, Between Scanners, and Sites.1 dayRepeatability and reproducibility of WSI were evaluated using the Average Positive Agreement Rate. Using a comparison of two reads with four possible outcomes (a=both reads detect the feature; b=read 1 fails to detect the feature; c=read 2 fails to detect the feature; d=both reads fail to detect the feature), APA = 2a/(2a+b+c). APA was used to assess outcomes in the following substudies: 1. Scans within scanner (Intra-scanner Precision): Scans are repeated within the scanner at the site. 2. Scanners within site (Inter-scanner Precision): Scans are repeated among the scanners at the site 3. Scans between Sites (Inter-site Precision): Scans are repeated within the scanner at the different sites.

Countries

United States

Participant flow

Participants by arm

ArmCount
NanoZoomer Whole Slide Imaging
Whole slide imaging using the Hamamatsu NanoZoomer S360MD Digital Slide Scanner System Hamamatsu NanoZoomer S360MD Digital Slide Scanner System: Detection of pathology features using whole slide imaging
540
Total540

Baseline characteristics

CharacteristicNanoZoomer Whole Slide Imaging
Race and Ethnicity Not Collected— Participants
Region of Enrollment
United States
540 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 0
other
Total, other adverse events
0 / 0
serious
Total, serious adverse events
0 / 0

Outcome results

Primary

Overall Percentage Agreement of Repeatability and Reproducibility Within Scanner, Between Scanners, and Sites.

Repeatability and reproducibility of WSI were evaluated using the Average Positive Agreement Rate. Using a comparison of two reads with four possible outcomes (a=both reads detect the feature; b=read 1 fails to detect the feature; c=read 2 fails to detect the feature; d=both reads fail to detect the feature), APA = 2a/(2a+b+c). APA was used to assess outcomes in the following substudies: 1. Scans within scanner (Intra-scanner Precision): Scans are repeated within the scanner at the site. 2. Scanners within site (Inter-scanner Precision): Scans are repeated among the scanners at the site 3. Scans between Sites (Inter-site Precision): Scans are repeated within the scanner at the different sites.

Time frame: 1 day

Population: Intra-scanner Precision: 3 separate scans on 1 scanner of 378 features read by 3 reading pathologists in 3 sessions each Inter-scanner Precision: 1 scan each of 378 features on 3 scanners read by 3 reading pathologists in 3 sessions each Inter-site Precision: 378 FOVs scanned on 1 scanner read by 3 reading pathologists at 3 sites in 1 session each

ArmMeasureValue (NUMBER)
NanoZoomer Whole Slide Imaging - Intra-scanner PrecisionOverall Percentage Agreement of Repeatability and Reproducibility Within Scanner, Between Scanners, and Sites.94.5 Average Positive Agreement Rate
NanoZoomer Whole Slide Imaging - Inter-scanner PrecisionOverall Percentage Agreement of Repeatability and Reproducibility Within Scanner, Between Scanners, and Sites.92.4 Average Positive Agreement Rate
NanoZoomer Whole Slide Imaging - Inter-site PrecisionOverall Percentage Agreement of Repeatability and Reproducibility Within Scanner, Between Scanners, and Sites.93.4 Average Positive Agreement Rate

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026